Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Larry Kotei
Institutions:
London School of Hygiene & Tropical Medicine,
MRC Unit the Gambia,
Medical Research Council
Observed institutions:
London School of Hygiene & Tropical Medicine,
MRC Unit the Gambia,
Medical Research Council
ORCID:
0009-0002-2640-9456
Observed ORCID:
0009-0002-2640-9456
OpenAlex ID:
A5093735584
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial
2024
·
Magnus Ochoge
, Ahmed Cherno Futa
, et al.
·
The Lancet
·
27
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study
2024
·
Adedapo O Bashorun
, Larry Kotei
, et al.
·
The Lancet Infectious Diseases
·
15
Collecting and reporting adverse events in low-income settings—perspectives from vaccine trials in the Gambia
2024
·
Andrew Ayi-Ashong Bruce
, Ama-Onyebuchi Umesi
, et al.
·
Trials
·
3
PDF
Human papillomavirus, sexually transmitted infections, and antimicrobial resistance in West Africa: Estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions: The PHASE survey protocol
2025
·
Adedapo Olufemi Bashorun
, Larry Kotei
, et al.
·
PLoS ONE
·
1
The design and use of ACASI to elicit sexual behaviour in the PHASE survey – the Gambian experience
2026
·
Adedapo O. Bashorun
, Larry Kotei
, et al.
·
Reproductive Health
Novel oral poliovirus vaccine type 2 is an important eradication tool, but reaching every last child remains vital
2024
·
Larry Kotei
, Ed Clarke
·
The Lancet Infectious Diseases
Show more works
View as search
Works count:
6
Citation count:
46
H-index:
3
I10-index:
2
Year
Topic
Type